Warner-Lambert and Rhone-Poulenc Rorer have agreed that the latter will codevelop and copromote the orally-active quinolone antibiotic sparfloxacin in the USA and Canada.
W-L notes that the compound will soon enter Phase III clinical trials in the USA as a treatment for community-acquired infections. Its investigational indications are community-acquired pneumonia, acute exacerbation of chronic bronchitis, complicated urinary tract infection and infections of the skin and skin structure.
Under the terms of the agreement, R-PR will codevelop sparfloxacin in this market in exchange for copromotion rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze